Argos Therapeutics, Inc. has announced that it is partnering with Adaptive Biotechnologies Corporation to study precise response patterns to Argos' investigational immunotherapies. Under the agreement, Adaptive will use its patented immune profiling immunoSEQ® Assay to enable a more in-depth characterization of the immune response induced by Argos's lead product candidate, AGS-003, which is currently being studied in the treatment of metastatic renal cell carcinoma, non-small cell lung cancer, and bladder cancer.
In addition, Argos is developing its second Arcelis® product candidate, AGS-004, for the treatment and the possible eradication of human immunodeficiency virus (HIV) in patients with HIV-infection or acquired immune deficiency syndrome (AIDS). The application of Adaptive's immune profiling technology in this setting will enable Argos to further characterize with greater precision the transfer of specific genetic signatures from each patient's HIV, through AGS-004, to a specific immune response against each patient's unique virus population.
"We are very excited to be entering into this important research agreement with Adaptive Biotechnologies," said Dr. Charles Nicolette, Argos's chief scientific officer. "Adaptive is our preferred partner because of their established expertise in offering high-throughput immune receptor repertoire characterization and advanced bioinformatics that are ideally suited to analyze precision of target-specific immune activation enabled by Arcelis administration with higher resolution."
"Argos is on the cutting edge of precision immunotherapy with their advanced Phase 3 immuno-oncology agent, and platform extension into individualized HIV treatment," said Chad Robins, Adaptive's president, chief executive officer and co-founder. "As the leader in immunosequencing, Adaptive's technology is well-suited to uncover the dynamics of the adaptive immune system response to Argos' therapies."